Volume 9, Issue 4 (12-2021)                   JoMMID 2021, 9(4): 225-229 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rostami T, Alijani N, Kiumarsi A, Rad S, Mirhoseini S A, Rostami M, et al . Tocilizumab in Post Hematopoietic Stem Cell Transplant COVID-19: A Pediatric Case Report. JoMMID 2021; 9 (4) :225-229
URL: http://jommid.pasteur.ac.ir/article-1-388-en.html
Tocilizumab in Post Hematopoietic Stem Cell Transplant COVID-19: A Pediatric Case Report
Tahereh Rostami , Neda Alijani , Azadeh Kiumarsi * , Soroush Rad , Seied Amirhosein Mirhoseini , Mohammadreza Rostami , Amir Hesabi , Seyed Ali Mousavi , Seied Asadollah Mousavi
Department of Pediatric Cell Therapy, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
Abstract:   (1653 Views)
Hematopoietic stem cell transplantation (HSCT) severely undermines the recipients' immune status and makes them prone to complications following viral infection. Here, we report a 3-year-old boy with mucopolysaccharidosis type VI who acquired SARS-CoV-2 infection after HSCT. The boy was diagnosed with SARS-CoV-2 during the post-transplant period (19 days after HSCT) when dealing with acute graft versus host disease (GVHD). He was successfully treated with remdesivir and tocilizumab and recovered. Well-timed treatment with tocilizumab might reduce the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia in the early post HSCT period.
Keywords: Post Hematopoietic Stem Cell Transplantation, COVID-19, Mucopolysaccharidosis
Full-Text [PDF 1283 kb]   (703 Downloads)    
Type of Study: Case Report | Subject: Host-pathogen interactions and susceptibility factors
Received: 2021/09/18 | Accepted: 2021/12/10 | Published: 2021/12/28
References
1. رفرنس های متنی مثل خروجی کراس رف را در اینجا وارد کرده و تایید کنید mohfw.gov.in [internet] Ministry of Health and Family Welfare. Government of India. Revised COVID-19 Clinical Management Protocol Algorithm (Adults); c2021. [cited 2021 Nov 02]. Available from: https://www.mohfw.gov.in/
2. Mohanty D, Mukherjee MB, Colah RB. Glucose-6-phosphate dehydrogenase deficiency in India. Indian J Pediatr. 2004; 71 (6): 525-9. [DOI:10.1007/BF02724295]
3. Mukherjee MB, Colah RB, Martin S, Ghosh K. Glucose-6-phosphate dehydrogenase (G6PD) deficiency among tribal populations of India - Country scenario. Indian J Med Res. 2015; 141 (5): 516-20.
4. Peters AL, Van Noorden CJ. Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. J Histochem Cytochem. 2009; 57 (11): 1003-11. [DOI:10.1369/jhc.2009.953828]
5. Takahashi T, Luzum JA, Nicol MR, Jacobson PA. Pharmacogenomics of COVID-19 therapies. NPJ Genom Med. 2020; 5 (1): 1-7. [DOI:10.1038/s41525-020-00143-y]
6. 6 fda.gov [internet]. Food and Drug Administration. FDA Drug Safety Communication: FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems; c2020. [cited 2021 Nov 02]. Available from: https://www.fda.gov/media/137250/download.
7. Beauverd Y, Adam Y, Assouline B, Samii K. COVID‐19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose‐6‐phosphate dehydrogenase deficiency. Eur J Haematol. 2020; 105 (3): 357-9. [DOI:10.1111/ejh.13432]
8. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 interim who solidarity trial results. N Engl J Med. 2021; 384 (6): 497-511. [DOI:10.1056/NEJMoa2023184]
9. RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020; 383 (21): 2030- 40. [DOI:10.1056/NEJMoa2022926]
10. Rosenstraus M, Chasin LA. Isolation of mammalian cell mutants deficient in glucose-6-phosphate dehydrogenase activity: linkage to hypoxanthine phosphoribosyl transferase. Proceedings of the National Academy of Sciences. 1975; 72 (2): 493-7. [DOI:10.1073/pnas.72.2.493]
11. Pai S, Sprenkle A, Do T, et al. Localization of loci for hypoxanthine phosphoribosyl transferase and glucose-6-phosphate dehydrogenase and biochemical evidence of non-random X chromosome expression from studies of a human X-autosome translocation. Proceedings of the National Academy of Sciences. 1980; 77 (5): 2810- 13. [DOI:10.1073/pnas.77.5.2810]
12. Torequl Islam. Mutation in hprt1 Gene or HPRT Deficiency May be a Restricting Progeny of Favipiravir in Covid-19. Sch Int J Tradit Complement Med. 2020; 3 (8): 162- 4. [DOI:10.36348/sijtcm.2020.v03i08.001]
13. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot Res. 2020; 73 (9): 593-602. [DOI:10.1038/s41429-020-0336-z]
14. Malek AE, Granwehr BP, Kontoyiannis DP. Doxycycline as a potential partner of COVID-19 therapies. IDCases. 2020; 21: e00864. [DOI:10.1016/j.idcr.2020.e00864]
15. Castro JZ, Fredeking T. Doxycycline modify the cytokine storm in patients with dengue and dengue hemorrhagic fever. Int J Infect Dis. 2010; 14: e44. [DOI:10.1016/j.ijid.2010.02.1586]
16. Bhowmick S, Dang A, Vallish BN, Dang S. Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review. Drug Saf. 2021; 44 (6): .635-44. [DOI:10.1007/s40264-021-01066-y]
17. Aldhaleei WA, Alnuaimi A, Bhagavathula AS. COVID-19 induced hepatitis B virus reactivation: a novel case from the United Arab Emirates. Cureus. 2020; 12 (6): e8645. [DOI:10.7759/cureus.8645]
18. Rodríguez‐Tajes S, Miralpeix A, Costa J, López‐Suñé E, Laguno M, Pocurull A, Lens S, Mariño Z, Forns X. Low risk of hepatitis b reactivation in patients with severe COVID‐19 who receive immunosuppressive therapy. J Viral Hepat. 2021; 28 (1): 89-94. [DOI:10.1111/jvh.13410]
19. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30 (3): 269-71. [DOI:10.1038/s41422-020-0282-0]
20. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020; 383 (19): 1813- 26. [DOI:10.1056/NEJMoa2007764]
21. covid19treatmentguidelines.nih.gov [internet] National Institutes of Health. Covid-19 Treatment Guidelines. Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19; c2021. [cited 2021 Nov 02]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/.
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.